October ___, 2024 Dear Pierre Sayad (“Executive”):Fennec Pharmaceuticals Inc. • October 30th, 2024 • Biological products, (no disgnostic substances) • North Carolina
Company FiledOctober 30th, 2024 Industry JurisdictionOn behalf of the Board of Directors of Fennec Pharmaceuticals, Inc. (“Fennec” or the “Company”), I am pleased to make you an executable offer to join the Company as its Chief Medical Officer. The purpose of this agreement is to clarify the terms of Executive’s “at will” employment with the Company, including Executive’s compensation level and benefit entitlements.
October ___, 2024 Dear Christiana Cioffi (“Executive”):Fennec Pharmaceuticals Inc. • October 30th, 2024 • Biological products, (no disgnostic substances) • North Carolina
Company FiledOctober 30th, 2024 Industry JurisdictionOn behalf of the Board of Directors of Fennec Pharmaceuticals, Inc. (“Fennec” or the “Company”), I am pleased to make you an executable offer to join the Company as its Chief Strategy Officer. The purpose of this agreement is to clarify the terms of Executive’s “at will” employment with the Company, including Executive’s compensation level and benefit entitlements.
October ___, 2024 Dear Terry Evans (“Executive”):Fennec Pharmaceuticals Inc. • October 30th, 2024 • Biological products, (no disgnostic substances) • North Carolina
Company FiledOctober 30th, 2024 Industry JurisdictionOn behalf of the Board of Directors of Fennec Pharmaceuticals, Inc. (“Fennec” or the “Company”), I am pleased to make you an executable offer to join the Company as its Chief Commercial Officer. The purpose of this agreement is to clarify the terms of Executive’s “at will” employment with the Company, including Executive’s compensation level and benefit entitlements.